TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06079489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure-Based Exercise Program
Description: Simple posture exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-Based Structured Exercise Program
Description: Progressive physical fitness and posture exercises
Study: NCT05335954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: noradrenaline
Description: noradrenaline
Study: NCT04780750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)
Study: NCT05848505

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal administration Dosage 2 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal administration Dosage 2 mcg/kg
Study: NCT05602948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Run, Jump & Fun' intervention
Description: The intervention can be designed e.g. to consist of morning sessions each schoolday (except days with PE) or with different time slots at different weekdays. Activities are mainly conducted by school personnel, but can be supplemented by activity sessions during recess once a week lead by older students. Further, to create variation and inspire teachers, external PA parties, for example instructors from local sports clubs are invited to conduct sessions for the students and deliver teaching materials.~To align with the aim of the Danish school system, activities must have a pedagogical purpose.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation (see Move \& Learn for more details).~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Move & Learn' intervention
Description: The physical activities in Move \& Learn are closely linked to the subject curricula. The bodily integrating in the learning task can vary between high bodily engagement and less demanding activities.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation. These strategies include; 1) Initial workshops and follow-up courses for school personnel to ensure ownership, empowerment and knowledge in order to implement the interventions, 2) Teaching materials and resources, like posters, booklets etc., 3) A set of core principles for the two different interventions to ensure that the interventions are implemented as intended, and 4) Mandatory school meetings for staff and heads to ensure motivation.~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA.
Study: NCT05058625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling plus normal volleyball training
Description: Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Normal volleyball training
Study: NCT05310487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 162
Description: The investigational product 162 is a novel neutralizing antibody targeting HBsAg, for the treatment of patients with chronic hepatitis B

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an intervention that appearance is the same as 162, but contains no active ingredients
Study: NCT05482152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led care by a nurse specialist in pain
Description: A nurse pain specialist consultation in patients in the experimental arm before they receive standard care by a physician.
Study: NCT05336331

Intervention type: PROCEDURE
Intervention: SG or a RYGB
Description: operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive

Intervention type: PROCEDURE
Intervention: SG or a RYGB
Description: operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive
Study: NCT06502873

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biological samples collection
Description: Collection of biological samples from the same cohorts: faeces, serum, intestinal biopsies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biological samples collection
Description: Collection of biological samples from the same cohorts: faeces, serum, intestinal biopsies
Study: NCT05902234

Intervention type: BEHAVIORAL
Intervention: interdiciplinary treatment
Description: Normal interdiciplinary treatment path
Study: NCT05264428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey
Description: Participants need to drink honey every day for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Participants need to drink water every day for four weeks.
Study: NCT04415463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multisegmented fully covered self-expandable metal stent
Description: Esophageal FC-SEMS
Study: NCT04998734

Intervention type: DIAGNOSTIC_TEST
Intervention: ASI-SR
Description: Psychometric properties of ASI-SR
Study: NCT05737186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitor
Description: dapagliflozin
Study: NCT06048354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex Oil
Description: The study foresees the intake of 2 capsules per day during 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex Powder
Description: The study foresees the intake of 2 capsules per day during 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 2 capsules per day during 84 days
Study: NCT06277102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music listening
Description: Music listening at postoperative day 1 and 2, 1 session per day, 20 minutes per session.
Study: NCT05798897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-601
Description: Multi-antigen specific CD4+ andCD8+ T cells
Study: NCT06116669

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron supplementation
Description: Iron supplements as 100 mg oral iron as FeSO4 given daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Description: Iron supplements as 100 mg oral iron as FeSO4 given daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Description: Iron supplements as 100 mg oral iron as FeSO4 given daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MenACWY vaccine
Description: MenACWY vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY vaccine
Description: MenACWY vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY vaccine
Description: MenACWY vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 vaccine
Description: Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsules given daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsules given daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Typhim Vi vaccine
Description: Typhim Vi vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi vaccine
Description: Typhim Vi vaccination given on day 28 to all participants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi vaccine
Description: Typhim Vi vaccination given on day 28 to all participants
Study: NCT05824234

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of a training centered around the notions of recovery with mental health services first year
Description: Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of a training centered around the notions of recovery with mental health services second year
Description: Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
Study: NCT05708326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5:2 Method (intermittent fasting regimen)
Description: Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 16/8 Method (intermittent fast regimen)
Description: Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
Study: NCT05424913

Intervention type: OTHER
Group type: OTHER
Intervention: research-specific blood sample
Description: blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers

Intervention type: OTHER
Group type: OTHER
Intervention: research-specific blood sample
Description: blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers

Intervention type: OTHER
Group type: OTHER
Intervention: research-specific blood sample
Description: blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers
Study: NCT05115604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioural intervention
Description: Six sessions of cognitive behavioural and psychoeducational therapy will be conducted to treat insomnia.
Study: NCT04960202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332
Description: PF-07321332 (tablet)
Study: NCT04766931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Study: NCT04960202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir (capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (tablet or capsule)
Study: NCT04766931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 Placebo
Description: Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
Study: NCT05367180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MISOLRE prevention program on sun risks
Description: Training of an ambassador class by a field coordinator Dissemination of the information by the ambassador class to the other classes of the school drawn by lot Transmission of an information document to parents on photoprotection to make them aware of the actions to adopt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MISOLRE prevention program on sun risks
Description: Training of an ambassador class by a field coordinator Dissemination of the information by the ambassador class to the other classes of the school drawn by lot Transmission of an information document to parents on photoprotection to make them aware of the actions to adopt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vivre avec le Soleil prevention program on sun risks
Description: Program is delivered directly by the teachers through pedagogical books : 10 workshops over a period of 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vivre avec le Soleil prevention program on sun risks
Description: Program is delivered directly by the teachers through pedagogical books : 10 workshops over a period of 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vivre avec le Soleil prevention program on sun risks
Description: Program is delivered directly by the teachers through pedagogical books : 10 workshops over a period of 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sun protection equipment
Description: Distribution of sunscreen, caps and sunglasses
Study: NCT04929743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTI Implant
Description: Placement of dental implants of 5.5 vs \>6.5 mm length

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTI Implant
Description: Placement of dental implants of 5.5 vs \>6.5 mm length
Study: NCT04855266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tilt Table Test
Description: A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Tilt Table Test
Description: A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.
Study: NCT04905147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride
Description: Mosapride citrate is prokinetic drug that selectively activates 5-HT4receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug 15 mg
Study: NCT05336253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVERYbody Project-Connect
Description: 3-week dissonance-based, group, online body image program (4.5 hours total)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Workbook
Description: Time-matched 3-week passive, individual workbook condition (4.5 hours total)
Study: NCT06138340

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Participants will be sedated and maintained by dexmedetomidine during the surgery.

Intervention type: DRUG
Intervention: Propofol
Description: Participants will be sedated and maintained by propofol during the surgery.
Study: NCT05591820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral parent training with optional booster sessions
Description: A brief and individually-tailored behavioral parent training program that combines stimulus control and contingency management techniques to treat children's behavioral difficulties in three (bi)weekly sessions and optional booster sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: The care that is usually provided by the clinical institutions to treat children's behavioral difficulties. There are no restrictions regarding type or duration of CAU (only the brief parent training will not be allowed) which may for example include psychoeducation, (long) parent training, child treatment (e.g., pharmacotherapy, cognitive behavioral therapy) or family therapy.
Study: NCT05956054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: needle type
Description: straight or curved

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: needle type
Description: straight or curved
Study: NCT04722926

Intervention type: OTHER
Intervention: PJI
Description: patients having had a PJI managed at the CRIOAc Lyon, with or without relapse
Study: NCT05226754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacerein
Description: After enrolment, patients will be randomized (n=20 group A) to receive diacerein capsules 50 mg every 12 hours for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: After enrolment, patients will be randomized (n=20 group A) to receive placebo capsules (lactose and magnesium stearate) every 12 hours for 10 days.
Study: NCT04774991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin for Oral Suspension
Description: Azithromycin will be administered as a single dose in oral suspension form for children as follows:~* Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~* For children 1 to \<12 months of age, weight-based dosing will be used~* For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin for Oral Suspension
Description: Azithromycin will be administered as a single dose in oral suspension form for children as follows:~* Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~* For children 1 to \<12 months of age, weight-based dosing will be used~* For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program.